2026-04-18T00:54:18Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/110382025-10-24T10:28:08Zcom_2072_378070com_2072_378040col_2072_378092

Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs Jang, Tyng-Yuan Liang, Po-Cheng Jun, Dae Won Jung, Jang Han Toyoda, Hidenori wang, chin-wen Vargas-Accarino, Elena Buti Ferret, Maria Institut Català de la Salut [Jang TY] Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, Kaohsiung Medical University and National Health Research Institutes, Kaohsiung, Taiwan. Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. [Liang PC, Wang CW] Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. [Jun DW] Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, South Korea. [Jung JH] Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. [Toyoda H] Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan. [Buti M, Vargas-Accarino E] Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBEREHD del Instituto Carlos III, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Hepatitis B - Tractament Transferases DISEASES::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis, Chronic::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis B, Chronic Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Transferases::Acyltransferases::Aminoacyltransferases::gamma-Glutamyltransferase ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis crónica::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis B crónica Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::transferasas::aciltransferasas::aminoaciltransferasas::gamma-glutamiltransferasa Mortality; Treatment Mortalitat; Tractament Mortalidad; Tratamiento Elevated serum gamma-glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)-related hepatocellular carcinoma. However, their role in predicting mortality in patients with CHB treated with nucleotide/nucleoside analogs (NAs) remains elusive. Altogether, 2843 patients with CHB treated with NAs were recruited from a multinational cohort. Serum GGT levels before and 6 months (Month-6) after initiating NAs were measured to explore their association with all-cause, liver-related, and non-liver-related mortality. The annual incidence of all-cause mortality was 0.9/100 person-years over a follow-up period of 17,436.3 person-years. Compared with patients who survived, those who died had a significantly higher pretreatment (89.3 vs. 67.4 U/L, p = 0.002) and Month-6-GGT levels (62.1 vs. 38.4 U/L, p < 0.001). The factors associated with all-cause mortality included cirrhosis (hazard ratio [HR]/95% confidence interval [CI]: 2.66/1.92–3.70, p < 0.001), pretreatment GGT levels (HR/CI: 1.004/1.003–1.006, p < 0.001), alanine aminotransferase level (HR/CI: 0.996/0.994–0.998, p = 0.001), and age (HR/CI: 1.06/1.04–1.07, p < 0.001). Regarding liver-related mortality, the independent factors included cirrhosis (HR/CI: 4.36/2.79–6.89, p < 0.001), pretreatment GGT levels (HR/CI: 1.006/1.004–1.008, p < 0.001), alanine aminotransferase level (HR/CI: 0.993/0.990–0.997, p = 0.001), age (HR/CI: 1.03/1.01–1.05, p < 0.001), and fatty liver disease (HR/CI: 0.30/0.15–0.59, p = 0.001). Pretreatment GGT levels were also independently predictive of non-liver-related mortality (HR/CI: 1.003/1.000–1.005, p = 0.03). The results remained consistent after excluding the patients with a history of alcohol use. A dose-dependent manner of <25, 25–75, and >75 percentile of pretreatment GGT levels was observed with respect to the all-cause mortality (trend p < 0.001). Pretreatment serum GGT levels predicted all-cause, liver-related, and non-liver-related mortality in patients with CHB treated with NAs. 2024-02-13T12:37:24Z 2024-02-13T12:37:24Z 2024-02 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Jang TY, Liang PC, Jun DW, Jung JH, Toyoda H, Wang CW, et al. Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs. Kaohsiung J Med Sci. 2024 Feb;40(2):188–97. 1607-551X https://hdl.handle.net/11351/11038 10.1002/kjm2.12771 37885338 001096107200001 http://hdl.handle.net/11351/11038 eng The Kaohsiung Journal of Medical Sciences;40(2) https://doi.org/10.1002/kjm2.12771 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Wiley Scientia